Association of Endogenous Pregnenolone, Progesterone, and Related Metabolites with Risk of Endometrial and Ovarian Cancers in Postmenopausal Women: The B ∼ FIT Cohort.
| Autor: | Trabert B; Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland. britton.trabert@nih.gov.; Department of Obstetrics and Gynecology, University of Utah, and Cancer Control and Population Sciences Research Program, Huntsman Cancer Institute, Salt Lake City, Utah., Geczik AM; Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland., Bauer DC; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.; Department of Medicine, University of California San Francisco, San Francisco, California., Buist DSM; Kaiser Permanente Washington Health Research Institute, Seattle, Washington., Cauley JA; Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania., Falk RT; Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland., Gierach GL; Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland., Hue TF; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California., Lacey JV Jr; Division of Health Analytics, Department of Computational and Quantitative Medicine, City of Hope, Duarte, California., LaCroix AZ; Division of Epidemiology, Department of Family and Preventive Medicine, University of California San Diego, San Diego, California., Michels KA; Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland., Tice JA; Department of Medicine, University of California San Francisco, San Francisco, California., Xu X; Leidos Biomedical Research, Inc., Frederick, Maryland., Brinton LA; Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland., Dallal CM; School of Public Health, University of Maryland, College Park, Maryland. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [Cancer Epidemiol Biomarkers Prev] 2021 Nov; Vol. 30 (11), pp. 2030-2037. Date of Electronic Publication: 2021 Aug 31. |
| DOI: | 10.1158/1055-9965.EPI-21-0669 |
| Abstrakt: | Background: Postmenopausal pregnenolone and/or progesterone levels in relation to endometrial and ovarian cancer risks have been infrequently evaluated. To address this, we utilized a sensitive and reliable assay to quantify prediagnostic levels of seven markers related to endogenous hormone metabolism. Methods: Hormones were quantified in baseline serum collected from postmenopausal women in a cohort study nested within the Breast and Bone Follow-up to the Fracture Intervention Trial (B∼FIT). Women using exogenous hormones at baseline (1992-1993) were excluded. Incident endometrial ( n = 65) and ovarian ( n = 67) cancers were diagnosed during 12 follow-up years and compared with a subcohort of 345 women (no hysterectomy) and 413 women (no oophorectomy), respectively. Cox models with robust variance were used to estimate cancer risk. Results: Circulating progesterone levels were not associated with endometrial [tertile (T)3 vs. T1 HR (95% confidence interval): 1.87 (0.85-4.11); P Conclusions: Using sensitive and reliable assays, this study provides novel data that endogenous progesterone levels are not strongly associated with incident endometrial or ovarian cancer risks. 17-hydroxypregnenolone was positively associated with ovarian cancer and inversely associated with endometrial cancer. Impact: While our results require replication in large studies, they provide further support of the hormonal etiology of endometrial and ovarian cancers. (©2021 American Association for Cancer Research.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|